-
Recombinant KMT2A (MLL1)-SET protein
Recombinant KMT2A (MLL1)-SET protein
- 中文名称：
- Recombinant KMT2A (MLL1)-SET protein
- 英文名称：
- Recombinant KMT2A (MLL1)-SET protein
- 品牌：
- AAA Biotech
- 品牌介绍：
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具，核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号：
- AAA59670
- 规格：
- 0.05 mg|1 mg|2x1 mg|3x1 mg|4x1 mg
- 保存建议：
- Recombinant proteins in solution are temperature sensitive and must be stored at -80 degree C to prevent degradation. Avoid repeated freeze/thaw cycles and keep on ice when not in storage.
Shipping Temp: Dry Ice
- 货期：
- 6-8周
- 纯度：
- The recombinant protein is >92% pure by SDS-PAGE.
- 产品形式：
- 20ug of Recombinant KMT2A (MLL1)-SET expressed in E Coli and supplied in 25mM Tris pH8.0, 300mM NaCl, 5% glycerol, 0.04% Triton X-100.
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 说明书：
Short Description: The peptide corresponding to amino acids 3735-3973 of the KMT2A (MLL1) protein (accession number NP_001184033.1) was expressed in E Coli. The peptide contains the SET domain of MLL that is responsible for methyltransferase activity. Recombinant Recombinant KMT2A (MLL1)-SET contains an N-terminal GST-Tag with a molecular weight of 53.7 kDa. Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila), or MLL, also known as HRX, is a Trithorax-group protein that function collectively to promote gene expression. MLL is a transcriptional coactivator that plays an essential role in regulating gene expression during early development and hematopoiesis. The protein contains multiple conserved functional domains. In particular, the SET domain is a conserved C-terminal domain that characterizes proteins of the MLL (mixed-lineage leukemia) family. The SET domain is responsible for its histone H3 lysine 4 (H3K4) methyltransferase activity which mediates chromatin modifications associated with epigenetic transcriptional activation. This protein is processed by the enzyme Taspase 1 into two fragments, MLL-C and MLL-N. These fragments reassociate and further assemble into different multiprotein complexes that regulate the transcription of specific target genes, including many of the HOX genes. Multiple chromosomal translocations involving this gene are the cause of certain acute lymphoid leukemias and acute myeloid leukemias. Alternate splicing results in multiple transcript variants. Recombinant KMT2A (MLL1)-SET protein can be used for enzyme kinetics and inhibitor screening studies.
Background: Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila), or MLL, also known as KMT2A or HRX, is a Trithorax-group protein that function collectively to promote gene expression. MLL is a transcriptional coactivator that plays an essential role in regulating gene expression during early development and hematopoiesis. The protein contains multiple conserved functional domains. In particular, the SET domain is a conserved C-terminal domain that characterizes proteins of the MLL (mixed-lineage leukemia) family. The SET domain is responsible for its histone H3 lysine 4 (H3K4) methyltransferase activity which mediates chromatin modifications associated with epigenetic transcriptional activation. This protein is processed by the enzyme Taspase 1 into two fragments, MLL-C and MLL-N. These fragments reassociate and further assemble into different multiprotein complexes that regulate the transcription of specific target genes, including many of the HOX genes. Multiple chromosomal translocations involving this gene are the cause of certain acute lymphoid leukemias and acute myeloid leukemias. Alternate splicing results in multiple transcript variants.
